BCRX
BioCryst Pharmaceuticals, Inc.
10.88
+
0.12
1.12%
9 x 10.86
15 x 10.87
bid
ask
16696 @ 03:50 PM
10.88+0.00 (0.00%)
Bearish
29
Bullish
76
sentiment
10.33
day range
10.95
7.89
52 week range
19.76
Prev Close10.76
Open10.84
Low10.33
High10.95
Volume3.45M
Avg. Volume4.96M
Market Cap2.02B
Inst. Own71.62%
Beta2.51
Short Ratio6.64
Div & Yield0.00 /
EPS-1.07
P/E
1yr Target17.45
50day MA9.60
200day MA13.40
^DJI
Dow Jones Industrial Average
31438.30
12:00 AM
-
62.40
0.20%
^IXIC
NASDAQ Composite
11524.60
12:00 AM
-
83.00
0.72%
^GSPC
S&P 500
3900.11
12:00 AM
-
11.63
0.30%
AAPL
141.98
+0.32 (0.23%)
Apple Inc.
141.66
1022 @ 03:50 PM
3 x 141.10
7 x 141.11
+
0.00
0.00%
GOOG
2338.00
+5.55 (0.24%)
Alphabet Inc.
2332.45
1 @ 03:50 PM
1 x 2329.99
1 x 2331.29
-
38.31
1.62%
AMZN
113.60
+0.38 (0.34%)
Amazon.com, Inc.
113.22
1 @ 03:50 PM
1 x 112.96
3 x 112.97
-
3.24
2.78%
MSFT
265.23
+0.34 (0.13%)
Microsoft Corporation
264.89
3 @ 03:50 PM
2 x 263.64
1 x 263.67
-
2.81
1.05%
BABA
118.82
+0.09 (0.08%)
Alibaba Group Holding Limited
118.73
1 @ 04:00 PM
1 x 117.00
1 x 120.30
+
1.11
0.94%
NFLX
189.14
+0.00 (0.00%)
Netflix, Inc.
189.14
49 @ 03:50 PM
1 x 188.15
1 x 188.22
-
1.71
0.90%
TSLA
735.81
+1.05 (0.14%)
Tesla, Inc.
734.76
14 @ 03:50 PM
1 x 732.31
1 x 732.66
-
2.36
0.32%
NVDA
168.97
+0.28 (0.17%)
NVIDIA Corporation
168.69
100 @ 03:50 PM
2 x 168.13
3 x 168.16
-
2.57
1.50%
AMD
86.25
+0.09 (0.10%)
Advanced Micro Devices, Inc.
86.16
500 @ 03:50 PM
3 x 86.06
12 x 86.08
-
0.92
1.06%
MU
58.95
+0.17 (0.29%)
Micron Technology, Inc.
58.78
389 @ 03:50 PM
4 x 58.71
2 x 58.72
+
0.34
0.58%
SPY
389.20
+0.61 (0.16%)
SPDR S&P 500 ETF Trust
388.59
1 @ 06:02 PM
13 x 388.80
5 x 388.87
-
1.49
0.38%
TQQQ
27.49
+0.17 (0.62%)
ProShares UltraPro QQQ
27.32
25 @ 03:50 PM
100 x 27.10
69 x 27.11
-
0.66
2.36%
BRK-A
414500.00
-3200.00 (0.77%)
Berkshire Hathaway Inc.
417700.00
11 @ 04:02 PM
13 x 412000.00
8 x 425555.00
+
299.00
0.07%
| Day Gain | ||
| Gain | ||
| Market Val | ||
| Costs | ||
| Cash | ||
| Portfolio | ||
| Realized | ||
| Dividend |
News
...
| ZIVO Bioscience (OTCMKTS:ZIVO) & BioCryst Pharmaceuticals (NASDAQ:BCRX) Critical Comparison | defenseworld.net • |
| BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX) | seekingalpha.com • |
| Stocks Rally as Major Indexes Look to End Losing Streaks | schaeffersresearch.com • |
| Here's What BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Shareholder Ownership Structure Looks Like | uk.sports.yahoo.com • |
| Strength Seen in BioCryst (BCRX): Can Its 5.5% Jump Turn into More Strength? | zacks.com • |
| Why BioCryst Pharmaceuticals Topped the Market Today | fool.com • |
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2022-08-04 | 2022-06 | -0.36 | N/A | N/A | N/A |
| 2022-05-05 | 2022-03 | -0.39 | -0.4 | -0.01 | -2.56% |
| 2022-02-23 | 2021-12 | -0.31 | -0.4 | -0.09 | -29.03% |
| 2021-11-03 | 2021-09 | -0.3 | -0.33 | -0.03 | -10.00% |
| 2021-08-05 | 2021-06 | -0.22 | -0.24 | -0.02 | -9.09% |
| 2021-05-06 | 2021-03 | -0.26 | -0.36 | -0.1 | -38.46% |
Upgrade / Downgrade
...
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2022-04-18 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2022-04-12 | RBC Capital | Upgrade | Sector Perform | |
| 2022-04-11 | B of A Securities | Downgrade | Buy | Neutral |
| 2022-04-11 | Oppenheimer | Upgrade | Outperform | |
| 2021-12-10 | Oppenheimer | Upgrade | Outperform | |
| 2021-11-04 | RBC Capital | Upgrade | Sector Perform |
Insider Holder
...
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2022-06-06 | ABERCROMBIE GEORGE B | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | ASELAGE STEPHEN J | Director | 46.59K | Stock Award(Grant) |
| 2022-06-06 | GALSON STEVEN K | Director | 12.87K | Stock Award(Grant) |
| 2022-06-06 | HEGGIE THERESA | Director | 30.23K | Stock Award(Grant) |
| 2022-06-06 | HUTSON NANCY J | Director | 77.94K | Stock Award(Grant) |
| 2022-06-06 | INGRAM ROBERT ALEXANDER | Director | 95.00K | Stock Award(Grant) |
Institution Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Blackrock Inc. | 14.10M | 229.30M | 7.60% |
| 2022-03-30 | Vanguard Group, Inc. (The) | 13.21M | 214.75M | 7.12% |
| 2022-03-30 | Baker Brothers Advisors, LLC | 12.71M | 206.68M | 6.85% |
| 2022-03-30 | FMR, LLC | 8.41M | 136.82M | 4.53% |
| 2022-03-30 | State Street Corporation | 7.46M | 121.34M | 4.02% |
| 2022-03-30 | Pictet Asset Management SA | 5.11M | 83.04M | 2.75% |
Fund Ownership
...
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2022-03-30 | Vanguard Total Stock Market Index Fund | 5.26M | 85.54M | 2.83% |
| 2022-04-29 | Fidelity Select Portfolios - Biotechnology | 4.19M | 38.95M | 2.26% |
| 2022-04-29 | iShares Russell 2000 ETF | 3.96M | 36.81M | 2.14% |
| 2022-04-29 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 3.71M | 34.50M | 2.00% |
| 2022-03-30 | Vanguard Extended Market Index Fund | 2.39M | 38.83M | 1.29% |
| 2022-03-30 | Vanguard Small-Cap Index Fund | 2.25M | 36.59M | 1.21% |
Dividend
...
| Dividend | Date |
|---|---|
| 0 | 2014-06-11 |
| 0 | 2014-06-05 |
| 0 | 2014-05-20 |
| 0 | 2014-05-16 |
| 0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
I should have bought inovio yesterday
-
@Willis I’ll say a 6. I think a buyout would be helpful , something to rock the boat?
-
@HT thx for the laugh, needed one today. I’m still a negative nelly here but you made me smile for a bit. 😂
-
Volume can’t even make it to 3 million.
-
Money tied up in a losing stock. It’s painfully obvious.
-
Low Volume. Same chart. No news because they have none. Got duped with dilution of shares.
-
If it was truly a Covid potential don’t you think the Company would do its own PR by now?
-
I might have to take a loss on this do nothing stock, trying to be patient but this is getting really old. Volume today is super low.
-
I don’t know why people think bcrx has a Covid play, if it did it would have been in the news already. No news because they have nothing good to report. Just more of the same ,float around in $4 ish all day, volume of 7 mil , someone here said news guaranteed AH yesterday. Guess not. Fr of mine out once it hits 4.64 , me same at 4.98.
-
I would not recommend this stock to anyone. Low volume, no catalyst, no news. Diluted shares, manipulated, never ending do nothing stock
-
4 million shares is low volume
-
Pleeeease get to 4.98 so I can get out already!
-
Going to be more of the same , this stock seriously is a loser. IMO
-
I want to believe the positive posts in here, but in the end the only news and info has to come from the Company itself which to date is still zilch.
-
Founded 1986 and highest was $6.29.
-
There will be no news because they have none. Only negative financial news.
-
On the wall.
-
Cannot wait to get to my average price and Exit this one. The financial news is not bright and the writing is in the wall.
-
Usbanking news. Zach analysts - $0.28 eps Hope it’s incorrect
-
Toilet Stock. More money will bleed out on Monday. That’s all it ever does. It is not a Covid stock. For myself, huge mistake.
-
BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX)
seekingalpha.com • -
Stocks Rally as Major Indexes Look to End Losing Streaks
schaeffersresearch.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com • -
What Wall Street Still Has Wrong. BioCryst To Become Next Rare Disease Giant
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
BioCryst Appoints Dr. Steven Galson to Board of Directors
globenewswire.com • -
BioCryst Stock Jumps After Pulling Out $200M Equity Raise
benzinga.com • -
BioCryst Withdraws Public Offering
globenewswire.com • -
BioCryst Pharma Stock Heads Higher Thursday: Here's Why
benzinga.com • -
3 Biotech Stocks That Could Rocket Higher
fool.com • -
BioCryst to Report Second Quarter 2021 Financial Results on August 5
globenewswire.com • -
BioCryst Pharmaceuticals - Orladeyo Revenue Will Drive Share Price
seekingalpha.com • -
7 A-Rated Biotech Stocks to Buy Now
investorplace.com • -
BioCryst Pharmaceuticals: An Orphan Disease Innovator With More Upside
seekingalpha.com • -
Is BioCryst a Good Stock to Buy Now?
fool.com • -
BioCryst: Solid Delivery And Follow Through
seekingalpha.com • -
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
globenewswire.com • -
BCRX Stock Price: $15 Target By Piper Sandler
pulse2.com • -
BioCryst Technical Levels To Watch
benzinga.com • -
BioCryst Short-Sellers Lose Control
seekingalpha.com • -
BioCryst Shares Slide As Reddit-Induced Rally Peters Out
benzinga.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com •
